-
Mashup Score: 1Log In - IDWeek - 3 year(s) ago
IDWeek 2021 attendees can access abstracts, sessions, exhibits, claim CME/CPE/MOC credit and print a certificate of attendance using one set of login
Source: IDWeekCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 7
The antibody cocktail of casirivimab and imdevimab significantly reduced viral loads in hospitalized patients with COVID-19 who were receiving low-flow or no supplemental oxygen, data presented at IDWeek showed. The combination therapy, known as REGEN-COV (Regeneron Pharmaceuticals), also reduced the risk for death within 28 days by around 36% (95% CI, 7.3%-55.7%) overall and around 56% (95% CI,
Source: www.healio.comCategories: Infectious Disease, Latest HeadlinesTweet-
The antibody cocktail of casirivimab and imdevimab significantly reduced viral loads in hospitalized patients with #COVID19 who were receiving low-flow or no supplemental oxygen, data presented at #IDWeek2021 showed. https://t.co/2A9WReL8Mo
-
-
Mashup Score: 22021 Closing Plenary - IDWeek - 3 year(s) ago
Harvey J. Alter, has been designated a Distinguished NIH Investigator, only one of 23 NIH scientists to hold that distinction. In his long career in clinical
Source: IDWeekCategories: Infectious Disease, Latest HeadlinesTweet-
If you missed the incredible end to #IDWeek2021, you can still catch it here! Dr. Harvey Alter & Dr. Anne Schuchat not only shared their stories & work, but also their poetry and music. Prepare to be inspired by their lives of service, and words of wisdom: https://t.co/Er1a1D1Rii https://t.co/6mmDQKBVHO
-
-
Mashup Score: 0Log In - IDWeek - 3 year(s) ago
IDWeek 2021 attendees can access abstracts, sessions, exhibits, claim CME/CPE/MOC credit and print a certificate of attendance using one set of login
Source: IDWeekCategories: Infectious Disease, Latest HeadlinesTweet-
Did you catch the Late Breaker Oral Abstract sessions? They are available on-demand now! Visit the IDWeek virtual platform to view https://t.co/u8gJuXqD3g #IDWeek2021 https://t.co/3HGdh8E1EM
-
-
Mashup Score: 0Oteseconazole promising for recurrent yeast infections - 3 year(s) ago
Oteseconazole was superior to fluconazole/placebo in the proportion of subjects with at least one culture-verified acute vulvovaginal candidiasis episode through week 50 in the intent-to-treat population.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Oteseconazole, an oral antifungal agent, is safe and effective in treating acute and recurrent yeast infections and in preventing recurrence of acute VVC episodes. https://t.co/IiisusBgwH #IDWeek2021 https://t.co/DsNFsG7n59
-
-
Mashup Score: 1
We are excited to welcome Drs. Heather Yun, Angie Myers, Ingrid Roig, and Jill Weatherhead to our panel discussion moderated by Drs. Laila Woc-Colburn, Wendy Armstrong, and Kris Bryant. These incredible women, leaders across the Infectious Diseases specialty, will be answering questions about their experiences and challenges during the COVID-19 pandemic.
Source: Zoom Video CommunicationsCategories: Infectious Disease, Latest HeadlinesTweet-
Register for Women in ID Oct. 7 @ 8:00 p.m. ET, our panelists will be answering questions about their experiences and challenges during the COVID-19 pandemic. Submit your questions in advance to learningce@shea-online.org & register to attend: https://t.co/jiVip9ZEqL #IDWeek2021 https://t.co/Y5lSv6kMl6
-
-
Mashup Score: 1A Final Chat with Our Guides for IDWeek 2021 - 3 year(s) ago
Dr. Carlos del Rio and Dr. Rajesh Gandhi, our infectious disease experts, offer their final thoughts on IDWeek 2021.
Source: cdn.jwplayer.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Final thoughts on #IDWeek2021: A chat with @CarlosdelRio7 and @RMKGandhi, our expert guides for the conference. https://t.co/riBlbbX8zT
-
-
Mashup Score: 2Oteseconazole promising for recurrent yeast infections - 3 year(s) ago
Oteseconazole was superior to fluconazole/placebo in the proportion of subjects with at least one culture-verified acute vulvovaginal candidiasis episode through week 50 in the intent-to-treat population.
Source: www.mdedge.comCategories: Latest Headlines, OBGYNTweet-
Oteseconazole, an oral antifungal agent, is safe and effective in treating acute and recurrent #yeastinfections and in preventing recurrence of acute VVC episodes. https://t.co/TY2GHeOKme #IDWeek2021 https://t.co/3vbgAWNC2M
-
-
Mashup Score: 7Log In - IDWeek - 3 year(s) ago
IDWeek 2021 attendees can access abstracts, sessions, exhibits, claim CME/CPE/MOC credit and print a certificate of attendance using one set of login
Source: IDWeekCategories: Infectious Disease, Latest HeadlinesTweet-
More than 1600 studies through virtual poster and oral abstracts are available to view! Ask authors questions through Oct 13, 2021. Come back often and enjoy: https://t.co/u8gJuXIdUO #IDWeek2021 https://t.co/yjGNL8zPxa
-
-
Mashup Score: 8Antibody Cocktail Reduces Chance of Developing COVID - 3 year(s) ago
Two long-acting antibodies — tixagevimab mixed with cilgavimab — reduced the risk of developing symptomatic COVID by 77% in a phase 3 trial of adults at high risk of contracting the virus.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Antibody cocktail reduces the chance of developing COVID https://t.co/WVWCxi2Ypr #IDWeek2021 https://t.co/1Rvzz9iOEK
-
Access #IDWeek2021 on demand until Dec. 31! Visit https://t.co/FIfAl9Ar81 to view on-demand content at your convenience. https://t.co/fuPokWyLEb